Clinical trials: Dose Finding Study
Chronic Kidney Disease
Study of Phosphate Levels in Patients With Chronic Kidney Disease
The purpose of this study is to investigate the ability of different doses of PA21 to lower serum phosphate levels, in patients with chronic kidney disease on maintenance hemodialysis.
- Trial name
- PA21 (NCT00824460)
- Testing
- 1.25 g PA21 (250 mg iron), 5.0 g PA21 (1,000 mg iron), 7.5 g PA21 (1,500 mg iron)
- Where
- 60 sites in United States, Bulgaria and 7 more
- Volunteers
- 154 people
- Sponsor
- Vifor Pharma
Acute Myeloid Leukemia
A Phase Ib, Open-label, Multi-center Dose-finding Study of Oral Panobinostat (LBH589) in Combination With Ara-C and Mitoxantrone as Salvage Therapy for Refractory or Relapsed Acute Myeloid Leukemia
The study will determine the maximal tolerated dose (MTD) of panobinostat administered in combination with a fixed combination of cytarabine (ara-C) and mitoxantrone in adult patients with relapsed or refractory acute myeloid…
- Trial name
- NCT01055483
- Testing
- panobinostat/LBH589B
- Where
- 6 sites in France, Germany
- Volunteers
- 59 people
- Sponsor
- Novartis Pharmaceuticals
Anesthesia, General
A Bridging Trial Comparing Sugammadex (Org 25969) at 1-2 Post-Tetanic Count (PTC) in Japanese Participants. Part A (P05957)
The objective of the trial was to establish the dose-response relation of sugammadex (Org 25969) given as a reversal agent of rocuronium or vecuronium at 1-2 PTC during sevoflurane anesthesia for Japanese participants.
- Trial name
- NCT00591786
- Testing
- Sugammadex
- Volunteers
- 100 people
- Sponsor
- Merck Sharp & Dohme LLC
Neoplasm Metastasis
Study of PF-07265807 in Participants With Metastatic Solid Tumors.
A First-in-Human Pharmacokinetic, Safety, and Tolerability Study of PF-07265807 as Monotherapy and in Combination in Participants with Advanced or Metastatic Solid Tumors
- Trial name
- NCT04458259
- Testing
- PF-07265807, Sasanlimab, Axitinib
- Where
- 33 sites in United States, Canada and 3 more
- Volunteers
- 88 people
- Sponsor
- Pfizer
Prostate Cancer
Phase II, Dose Finding Study of GTx-758
The purpose of this study is to determine the appropriate loading and maintenance dose of GTx-758 to reach and maintain castration for the duration of the study.
- Trial name
- NCT01393119
- Testing
- GTx-758
- Where
- 21 sites in United States
- Volunteers
- 77 people
- Sponsor
- GTx
Advanced Solid Tumors
A Study of MRG003 in Patients With Advanced Solid Tumors
The objective of this study is to assess the safety, efficacy, and pharmacokinetics of MRG003, as well as immunogenicity as defined by the incidence of anti-drug antibody (ADA) of MRG003 in patients with advanced solid tumors…
- Trial name
- NCT04868344
- Testing
- MRG003
- Where
- China
- Volunteers
- 61 people
- Sponsor
- Lepu Biopharma Co., Ltd.
Tetanus
Study to Compare the Anti-tetanus Neutralizing Antibody Titers and Safety of TNM002 Injection With Human Tetanus Immunoglobulin or Placebo in Adult Volunteers
The primary objective is to compare the anti-tetanus neutralizing antibody titers of TNM002 Injection with human tetanus immunoglobulin (HTIG) following a single intramuscular (IM) injection in Chinese adult volunteers.
- Trial name
- NCT05625477
- Testing
- TNM002 (low dose), TNM002 (medium dose), TNM002 (high dose)
- Where
- 4 sites in China
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Zhuhai Trinomab Pharmaceutical Co., Ltd.
Congenital Hearing Loss
a Study in Subjects With Otoferlin Mutation-related Hearing Loss Using RNA Base-eDiting Therapy(SOUND)
The purpose of the study is to determine whether HG205 as CRISPR/Cas13 RNA base-editing therapy is safe and effective for the treatment of hearing loss caused by p.Q829X mutation in OTOF gene.
- Trial name
- NCT06025032
- Testing
- HG205
- Where
- China
- Sponsor
- HuidaGene Therapeutics Co., Ltd.
Ocular Hypertension, Open Angle Glaucoma
Dose Finding Clinical Trial With SYL040012 to Evaluate the Tolerability and Effect on Intraocular Pressure in Subjects With Ocular Hypertension or Open Angle Glaucoma
The aim of this dose-finding clinical trial is to evaluate the systemic tolerability, local tolerability and intraocular pressure lowering effect of three different doses of SYL040012 in subjects with ocular hypertension or…
- Trial name
- NCT01739244
- Testing
- SYL040012
- Where
- 11 sites in Estonia, Germany and 1 more
- Volunteers
- 80 people
- Sponsor
- Sylentis, S.A.
Parkinson Disease
A Placebo- and Active-Controlled Study of Preladenant in Early Parkinson's Disease (PD) (P05664)
This is a one year, 2-part study to determine the efficacy and safety of preladenant, an adenosine type 2a (A2a) receptor antagonist.
- Trial name
- PARADYSE (NCT01155479)
- Testing
- Preladenant 2 mg tablet, Preladenant 5 mg tablet, Preladenant 10 mg tablet
- Volunteers
- 1,022 people
- Sponsor
- Merck Sharp & Dohme LLC
Peripheral T-cell Lymphoma
Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL)
The primary objective of this study is to determine the Maximum Tolerated Dose (MTD) for belinostat when combined with CHOP regimen and establish the recommended belinostat dose for the Phase 3 study.
- Trial name
- NCT01839097
- Testing
- Belinostat, CHOP
- Where
- 8 sites in United States
- Volunteers
- 23 people
- Sponsor
- Acrotech Biopharma Inc.
Phenylketonuria
A Dose-finding Study to Evaluate mRNA-3210 in Participants With Phenylketonuria
The main goal of this study is to assess the safety, and tolerability of multiple doses of mRNA-3210 in participants with phenylketonuria (PKU).
- Trial name
- NCT06147856
- Testing
- mRNA-3210
- Sponsor
- ModernaTX, Inc.
Pain, Peripheral Neuropathy
The Purpose of This Study is to Determine if Tetrodotoxin (TTX) is Effective in the Treatment of Pain Resulting From Chemotherapy Treatment
Chemotherapy-induced peripheral neuropathy (CIPN) is a major dose-limiting side effect of many chemotherapeutic agents including vincristine, paclitaxel, cisplatin, oxaliplatin, bortezomib and ixabepilone.
- Conditions
- Pain, Peripheral Neuropathy, Neuropathic Pain
- Trial name
- TTX-CINP-201 (NCT01655823)
- Testing
- Tetrodotoxin
- Where
- 23 sites in United States
- Volunteers
- 125 people
- Sponsor
- Wex Pharmaceuticals Inc.
Stroke
Efficacy of SUN N4057 in Subjects With Acute Ischemic Stroke and Measurable Penumbra on Magnetic Resonance Imaging (MRI)
This research study is designed to evaluate the safety, tolerability, and efficacy of SUN N4057 (piclozotan) in subjects with acute ischemic stroke within 9 hours of the onset of symptoms.
- Trial name
- NCT00272909
- Testing
- piclozotan low dose, piclozotan high dose
- Where
- 47 sites in United States, Belgium and 5 more
- Volunteers
- 43 people
- Sponsor
- Daiichi Sankyo
Gout
Dose Finding Study to Evaluate Safety and Efficacy of 3 Dosages of SAP 001.
The aim of this study is to confirm the safety and pharmacological characteristics of SAP-001, evaluate its efficacy in lowering sUA and tophus burden, and identify the appropriate dose regimen for future studies in adult…
- Trial name
- NCT05690204
- Testing
- SAP-001
- Where
- 16 sites in United States, Puerto Rico
- Volunteers
- 87 people
- Sponsor
- Shanton Pharma Pte. Ltd.
Diabetic Macular Edema(DME)
The Study to YD312 Tablet in Patients With Diabetic Macular Edema
This study objectives is to evaluate the efficacy of YD312 to improve visual acuity in patients with diabetic macular edema (DME) compared to placebo and determine optimal dose of phase 2b study.
- Trial name
- NCT03635814
- Testing
- YD312 50mg, YD312 150mg, YD312 350mg
- Where
- 20 sites in United States, South Korea
- Volunteers
- 100 people
- Sponsor
- YD Global Life Science Co., Ltd.
Migraine
A Dose-Finding Study of MK-1602 in the Treatment of Acute Migraine (MK-1602-006)
The purpose of this study is to assess the effectiveness, safety and tolerability of a range of doses of MK-1602 versus placebo in the treatment of acute migraine.
- Trial name
- NCT01613248
- Testing
- MK-1602, Rescue medication
- Volunteers
- 834 people
- Sponsor
- Allergan
Type II Diabetes Mellitus
A Study of Different Doses of Sitagliptin (MK-0431) in Participants With Type 2 Diabetes Mellitus (MK-0431-014)
A study of different doses of MK-0431 in participants with type 2 diabetes mellitus. There have been 3 extensions to the base study (Extension 1: up to Week 52, Extension 2: up to Week 106, and Extension 3: up to Week 158).
- Trial name
- NCT00481663
- Testing
- Sitagliptin, Metformin, Rescue
- Volunteers
- 555 people
- Sponsor
- Merck Sharp & Dohme LLC
Metastasis, Locally Advanced Solid Tumor
Trial of XRD-0394, a Kinase Inhibitor, in Combination With Palliative Radiotherapy in Advanced Cancer Patients
XRD-0394 is a novel, potent, oral, small molecule dual inhibitor of ataxia telangiectasia mutated kinase (ATM) and deoxyribonucleic acid (DNA)-dependent protein kinase (DNA-PK) that has selectivity compared with other…
- Conditions
- Metastasis, Locally Advanced Solid Tumor, Recurrent Cancer
- Trial name
- NCT05002140
- Testing
- XRD-0394, Palliative radiotherapy
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- XRad Therapeutics Inc
Lupus Erythematosus, Systemic
A Phase II Study to Evaluate Safety and Efficacy of ALX-0061 in Subjects With Systemic Lupus Erythematosus
Primary objective: To assess the efficacy and safety of different dose regimens of ALX-0061 administered subcutaneously (s.c.) to subjects with moderate to severe active, seropositive systemic lupus erythematosus (SLE) compared…
- Trial name
- NCT02437890
- Testing
- ALX-0061
- Where
- 118 sites in United States, Argentina and 15 more
- Volunteers
- 312 people
- Sponsor
- Ablynx, a Sanofi company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.